Doporučené léčebné postupy v hematologii

15. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic
syndrome with chromosome 5q deletion. N Engl J Med 2006;
355: 1456-65.
16. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic
scoring system for predicting survival and leukemic evolution
in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-10.
17. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of
reduced-intensity conditioning and conventional high-dose conditioning
for allogeneic hematopoietic stem cell transplantation using
HLA-identical sibling donors in myelodysplastic syndromes. Blood
2006; 108: 836-846.
18. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin
for patients with myelodysplastic syndrome. Br J Haematol 1997;
99: 699-705.
19. Parker JE, Shafi T, Pagliuca A, et al. Allogeneic stem cell transplan-
tation in the myelodysplastic syndromes: interim results of outcome
following reduced-intensity conditioning compared with standard
preparative regimens. Br J Haematol 2002; 119: 144–154.
20. Schrezenmeier H, Passweg JR, Marsh JCW, et al. Worse outcome
and more GVHD with peripheral blood progenitor cells than bone
marrow in HLA-matched sibling donor transplants for young patients
with severe acquired aplastic anemia. Blood 2007; 110: 1397-
1400.
21. Sierra J, Perez WS, Rozman C. et al. Bone marrow transplantation
from HLA-identical siblings as treatment for myelodysplasia. Blood
2002; 100: 1997-2004.
Vypracování doporučeného postupu bylo podpořeno výzkumným záměrem
00023736 MZd ČR.
44 Transfuze Hematol. dnes, 16, 2010